About this episode

Dr. Lisa Hicks and Dr. Joseph Mikhael discuss the updated ASCO and Ontario Health guideline on the treatment of multiple myeloma.

Dr. Lisa Hicks and Dr. Joseph Mikhael discuss the updated guideline from ASCO and Ontario Health (Cancer Care Ontario) on the treatment of multiple myeloma. They cover recommendations for therapeutic options across smoldering multiple myeloma, transplant eligible multiple myeloma, transplant ineligible multiple myeloma, and relapsed or refractory multiple myeloma. They highlight the importance of shared decision making and patient-centric care. They comment on the explosion of new treatment options in this space and the impetus for this guideline becoming a living guideline, which will be updated on an ongoing, regular basis. Read the full guideline, "Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline" at www.asco.org/hematologic-malignancies-guidelines . TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/hematologic-malignancies-guidelines . Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-02587 Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's…

People in this episode

Host: Brittany Harvey

Guests: Dr. Lisa Hicks, Dr. Joseph Mikhael

Topics covered

• multiple myeloma
• treatment guidelines
• oncology
• patient-centric care
• shared decision making
• therapeutic options

Keywords

• multiple myeloma
• treatment options
• guideline
• ASCO
• oncology
• patient care
• shared decision making

Mentioned in this episode

Organizations: American Society of Clinical Oncology, Ontario Health, Cancer Care Ontario, Journal of Clinical Oncology

More episodes of ASCO Guidelines

• Systemic Treatment of Thyroid Cancer Guideline · April 1, 2026 · 23 min
• Patient-Clinician Communication Guideline Update · March 10, 2026 · 31 min
• Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer Guideline Update · February 26, 2026 · 29 min
• White Blood Cell Growth Factors Guideline Update · February 25, 2026 · 23 min
• Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2026.3.0 Part 2 · February 3, 2026 · 20 min
• Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2026.3.0 Part 1 · February 3, 2026 · 18 min

Explore listener stats, chart rankings, contacts and more on the ASCO Guidelines podcast page.